Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 27 February 2018, 09:33 HKT/SGT
Share:
    

Source: Eisai
Eisai: Launch of "Dementia Support" Insurance to Provide for Dementia in Japan
Jointly Developed by Eisai and Saint-Plus

TOKYO, Feb 27, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that it has jointly developed with Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. dementia diagnosis lump-sum insurance "Dementia Support" in Japan, and that Saint Plus has launched this product today.

According to the Ministry of Health, Labour and Welfare, the number of people with dementia was approximately 4.62 million in 2012, and is expected to increase to approximately 7 million by 2025. According to a survey on dementia conducted by Eisai of 224 men and women aged 40 and older, the highest source of anxiety was "personal or family member's incidence of dementia" followed by "burden of nursing care on family" and "financial burden caused by dementia care," while the top three factors for reducing anxiety were "consulting with healthcare and nursing care professionals, the government and other organizations," "preparing savings and other finances" and "obtaining information on preventing dementia."

Eisai and Saint-Plus entered into a joint development agreement for insurance that aims to reduce anxiety over dementia in December 2016, and jointly developed "Dementia Support" small amount short-term insurance to provide for dementia. For beneficiaries aged 40 to 90, submitting an application is possible with a simple notice even after becoming certified as requiring long-term care and beneficiaries receive a lump-sum payment upon diagnosis of specific conditions such as organic dementia. In addition, as ancillary services, policyholders and beneficiaries may be provided with various kinds of useful information on dementia as well as introduced to services including telephone consultation services operated by the non-profit organization Alzheimer's Association Japan about matters such as symptoms of dementia and concerns about nursing care.
The sale of insurance, including provision of ancillary services, is handled by Saint-Plus, and Eisai receives royalties relating to joint development.

About "Dementia Support" Insurance to Provide for Dementia

Sales of "Dementia Support" insurance are conducted by Saint-Plus.
1. Provides assurance against organic dementia
2. Submitting an application is possible even after becoming certified as requiring long-term care
3. A medical certificate is not required from a physician, it is possible to apply with just a simple notice
4. There are three courses for benefit payments
5. Insurance premiums start from 163 yen per month (60 year old male: 200,000 yen rider course)
6. People aged 40 years old up to and including people aged 90 years old may apply
7. It is possible to continue up to age 100 by renewing the policy

Saint-Plus' website for product information: https://www.saint-plus-ins.co.jp/sasae/ (available in Japanese only)

For inquiries about the product, please contact Saint-Plus: 0120-786-765 (Weekdays 9:30 to 17:00, excluding Saturdays, Sundays, public holidays, the New Year and other holiday periods, for residents in Japan only)

About Saint-Plus Small Amounts and Short Term Insurance Co., Ltd.

The Saint-Care Group, which provides comprehensive health care services, hears the voices from the field of nursing care and welfare, and in wanting to provide a "new support framework" that will be useful to those who truly need nursing care and their families, Saint-Plus Small Amounts and Short Term Insurance Co., Ltd. developed and markets Japan's first private nursing care insurance as a nursing care business.

For more information about Saint-Plus Small Amounts and Short Term Insurance Co., Ltd., please visit https://www.saint-plus-ins.co.jp/ (available in Japanese only)


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: